| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
National Cancer Institute, Bethesda, Maryland, and the International Business Machines Corporation, Endicott, New York
Existing methods for separation and collection of leukocytes permit collection of only limited quantities of leukocytes. An instrument has been designed to process large volumes of blood on a continuous flow basis. The instrument collects venous blood, separates leukocytes in a centrifuge, and reinjects the red cells, plasma, and platelets. The separation process is 3060% efficient in vitro at flow rates up to 50 ml/min. In vivo tests demonstrated safety, sterility, lack of hemolysis, and adequate anti-coagulation. However, leukocyte recovery in vivo is low (under 20%). If this poor in vivo recovery can be overcome, the instrument should prove useful for collection of large quantities of leukocytes.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |